Tae-Youn Jun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tae-Youn Jun has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Jae-Min Kim
Department of Psychiatry, Chonnam National University Medical School, Gwangju, Korea
5 shared publicationsMin-Soo Lee
Department of Psychiatry, Korea University College of Medicine, Seoul, Korea
5 shared publicationsJung-Bum Kim
Department of Psychiatry, Keimyung University School of Medicine, Daegu, Korea
4 shared publicationsYoung Sup Woo
Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
4 shared publications- Chi-Un Pae
Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
3 shared publications - Hyeon Woo Yim
Department of Preventive Medicine, College of Medicine The Catholic University of Korea Seoul Korea
3 shared publications
Latest Publications
- Open Access
- 30 November 2017
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 15 (4) , 391-401
Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study
Young Sup Woo, Roger S. McIntyre, Jung-Bum Kim, Min-Soo Lee, Jae-Min Kim, Hyeon Woo Yim, and Tae-Youn Jun. Clin Psychopharmacol Neurosci 2017;15:391-401. https://doi.org/10.9758/cpn.2017.15.4.391
- 30 November 2017
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 15 (4) , 391-401
Open AccessParoxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study
Young Sup Woo, Roger S. McIntyre, Jung-Bum Kim, Min-Soo Lee, Jae-Min Kim, Hyeon Woo Yim, and Tae-Youn Jun. Clin Psychopharmacol Neurosci 2017;15:391-401. https://doi.org/10.9758/cpn.2017.15.4.391
- 1 January 2017
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 27, S451-S452
Genes Involved In Neurodevelopment, Neuroplasticity And Bipolar Disorder: Cacna1c, Chrna1 And MAPK1
- 1 January 2017
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 27, S451-S452
Genes Involved In Neurodevelopment, Neuroplasticity And Bipolar Disorder: Cacna1c, Chrna1 And MAPK1
- 1 September 2014
- Published by Elsevier in Journal of Affective Disorders
- Vol. 166, 79-85
Is the Psychotic Depression Assessment Scale a useful diagnostic tool?: The CRESCEND study
- 1 September 2014
- Published by Elsevier in Journal of Affective Disorders
- Vol. 166, 79-85
Is the Psychotic Depression Assessment Scale a useful diagnostic tool?: The CRESCEND study
- Open Access
- 1 January 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10) , e105860
Relationship of Temperament and Character in Remitted Depressed Patients with Suicidal Ideation and Suicide Attempts—Results from the CRESCEND Study
The aim of this study was to evaluate the Temperament and Character Inventory (TCI) scores of a sample of Korean patients with remitted depression who had attempted suicide and reported suicidal ideation and to compare their scores with those of remitted depressed patients without suicidal ideation. Adult depression patients who had completed 12 weeks of follow-up (N = 138) were divided into three groups: patients with a history of suicide attempts (N = 23); patients with current suicidal ideation (N = 59); and patients without current suicidal ideation (N = 56). After controlling for covariates, no significant differences were found among the three groups on any measure of temperament or character except self-directedness and self-transcendence. The self-transcendence scores of the lifetime suicide-attempt group were significantly higher compared with those of the suicidal-ideation group; post hoc analysis revealed that self-directedness was significantly lower in the suicide-attempt group compared with the non-suicidal group. The results from the present study suggest that remitted depression patients with a history of suicide attempts do not differ from non-attempters in temperament, but do differ in certain character traits.
- 1 January 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10) , e105860
Open AccessRelationship of Temperament and Character in Remitted Depressed Patients with Suicidal Ideation and Suicide Attempts—Results from the CRESCEND Study
The aim of this study was to evaluate the Temperament and Character Inventory (TCI) scores of a sample of Korean patients with remitted depression who had attempted suicide and reported suicidal ideation and to compare their scores with those of remitted depressed patients without suicidal ideation. Adult depression patients who had completed 12 weeks of follow-up (N = 138) were divided into three groups: patients with a history of suicide attempts (N = 23); patients with current suicidal ideation (N = 59); and patients without current suicidal ideation (N = 56). After controlling for covariates, no significant differences were found among the three groups on any measure of temperament or character except self-directedness and self-transcendence. The self-transcendence scores of the lifetime suicide-attempt group were significantly higher compared with those of the suicidal-ideation group; post hoc analysis revealed that self-directedness was significantly lower in the suicide-attempt group compared with the non-suicidal group. The results from the present study suggest that remitted depression patients with a history of suicide attempts do not differ from non-attempters in temperament, but do differ in certain character traits.
- 1 November 2013
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 28 (6) , 322-329
Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder
Patients with chronic or recurrent major depressive disorder (MDD) have faced a dearth of treatment options. The present study evaluated the effectiveness and tolerability of aripiprazole augmentation for the treatment of chronic or recurrent MDD. This was the first 12-week prospective, multicentre, open-label study of the effectiveness and tolerability of flexibly dosed aripiprazole as an augmentation to ongoing antidepressant treatment in patients with chronic or recurrent MDD. The primary outcome measure for effectiveness was changes between baseline and endpoint (week 12) in total scores on the Montgomery-Asberg Depression Rating Scale. Adverse events (AEs) occurring throughout the trial are also reported. The Montgomery-Asberg Depression Rating Scale total scores decreased significantly between the baseline and the endpoint (magnitude of difference=-11.6, P<0.0001). At the endpoint, the response rate was 55.2% and the remission rate was 41.3%. Adjunctive aripiprazole treatment administered from week 1 through the endpoint was associated with remission and significant treatment responses. More than half (55.8%) of those taking adjunctive aripiprazole completed the study and relatively few patients discontinued participation because of AEs. None of the patients discontinued participation in the study because of an inadequate therapeutic response. Common AEs included headache, akathisia, insomnia and constipation. The mean dose of aripiprazole at the endpoint was 6.6 mg/day. Adjunctive aripiprazole may be effective and tolerable for patients with chronic or recurrent MDD. Adequately powered and controlled clinical trials should be conducted to confirm our open-label study findings.
- 1 November 2013
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 28 (6) , 322-329
Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder
Patients with chronic or recurrent major depressive disorder (MDD) have faced a dearth of treatment options. The present study evaluated the effectiveness and tolerability of aripiprazole augmentation for the treatment of chronic or recurrent MDD. This was the first 12-week prospective, multicentre, open-label study of the effectiveness and tolerability of flexibly dosed aripiprazole as an augmentation to ongoing antidepressant treatment in patients with chronic or recurrent MDD. The primary outcome measure for effectiveness was changes between baseline and endpoint (week 12) in total scores on the Montgomery-Asberg Depression Rating Scale. Adverse events (AEs) occurring throughout the trial are also reported. The Montgomery-Asberg Depression Rating Scale total scores decreased significantly between the baseline and the endpoint (magnitude of difference=-11.6, P<0.0001). At the endpoint, the response rate was 55.2% and the remission rate was 41.3%. Adjunctive aripiprazole treatment administered from week 1 through the endpoint was associated with remission and significant treatment responses. More than half (55.8%) of those taking adjunctive aripiprazole completed the study and relatively few patients discontinued participation because of AEs. None of the patients discontinued participation in the study because of an inadequate therapeutic response. Common AEs included headache, akathisia, insomnia and constipation. The mean dose of aripiprazole at the endpoint was 6.6 mg/day. Adjunctive aripiprazole may be effective and tolerable for patients with chronic or recurrent MDD. Adequately powered and controlled clinical trials should be conducted to confirm our open-label study findings.
- Open Access
- 28 August 2013
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 11 (2) , 67-71
Association between FAT Gene and Schizophrenia in the Korean Population
Jung YE, et al. Clin Psychopharmacol Neurosci. 2013 Aug;11(2):67-71. http://dx.doi.org/10.9758/cpn.2013.11.2.67
- 28 August 2013
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 11 (2) , 67-71
Open AccessAssociation between FAT Gene and Schizophrenia in the Korean Population
Jung YE, et al. Clin Psychopharmacol Neurosci. 2013 Aug;11(2):67-71. http://dx.doi.org/10.9758/cpn.2013.11.2.67
- 17 September 2011
- Published by Springer Nature in Quality of Life Research
- Vol. 21 (6) , 967-974
Factors associated with subjective quality of life in Korean patients with depressive disorders: the CRESCEND study
- 17 September 2011
- Published by Springer Nature in Quality of Life Research
- Vol. 21 (6) , 967-974
Factors associated with subjective quality of life in Korean patients with depressive disorders: the CRESCEND study
- 1 May 2011
- Published by Korean Clinical Psychology Association in Korean Journal of Clinical Psychology
- Vol. 30 (2) , 553-570
Classification and Characteristics of Depression Subtypes: Latent Class Analysis
- 1 May 2011
- Published by Korean Clinical Psychology Association in Korean Journal of Clinical Psychology
- Vol. 30 (2) , 553-570
Classification and Characteristics of Depression Subtypes: Latent Class Analysis